Avalo Therapeutics (NASDAQ:AVTX) Stock Gets Price Target Reduction from BTIG Research

by · The Cerbat Gem

Avalo Therapeutics (NASDAQ:AVTX – Get Free Report) had its price objective lowered by research analysts at BTIG Research to $10.00 in a research report issued on Friday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. BTIG Research‘s price objective indicates a potential upside of 34.23% from the company’s current price.

A number of other analysts also recently commented on the company. Weiss Ratings upgraded Avalo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Leerink Partners initiated coverage on Avalo Therapeutics in a research report on Monday, July 6th. They issued an “outperform” rating and a $38.00 price objective on the stock. Guggenheim reiterated a “neutral” rating on shares of Avalo Therapeutics in a report on Friday. Cantor Fitzgerald reissued an “overweight” rating on shares of Avalo Therapeutics in a research note on Wednesday, September 16th. Finally, HC Wainwright reaffirmed a “neutral” rating on shares of Avalo Therapeutics in a research report on Friday. Ten investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $40.30.

Read Our Latest Research Report on AVTX

Avalo Therapeutics Stock Performance

Shares of AVTX stock opened at $7.45 on Friday. The stock’s 50 day simple moving average is $16.30 and its 200 day simple moving average is $16.67. Avalo Therapeutics has a twelve month low of $6.85 and a twelve month high of $24.27. The company has a market capitalization of $399.54 million, a price-to-earnings ratio of -1.70 and a beta of 0.68.

Avalo Therapeutics (NASDAQ:AVTX – Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.83) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.25). On average, analysts forecast that Avalo Therapeutics will post -2.95 EPS for the current fiscal year.

Insider Buying and Selling

In other Avalo Therapeutics news, CFO Christopher Sullivan sold 12,394 shares of the business’s stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $16.33, for a total transaction of $202,394.02. Following the sale, the chief financial officer directly owned 39,900 shares of the company’s stock, valued at $651,567. The trade was a 23.70% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 24,258 shares of company stock worth $415,434. 4.46% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of AVTX. Squarepoint Ops LLC boosted its position in Avalo Therapeutics by 624.9% during the second quarter. Squarepoint Ops LLC now owns 589,245 shares of the company’s stock valued at $10,889,000 after acquiring an additional 507,960 shares during the last quarter. Seven Fleet Capital Management LP boosted its position in Avalo Therapeutics by 34.3% during the second quarter. Seven Fleet Capital Management LP now owns 770,765 shares of the company’s stock valued at $14,244,000 after acquiring an additional 196,882 shares during the last quarter. Braidwell LP bought a new stake in Avalo Therapeutics during the second quarter valued at $30,107,000. Wellington Management Group LLP bought a new stake in Avalo Therapeutics during the second quarter valued at $1,945,000. Finally, Bank of New York Mellon Corp bought a new stake in Avalo Therapeutics during the second quarter valued at $1,897,000. 87.06% of the stock is owned by institutional investors.

Key Headlines Impacting Avalo Therapeutics

Here are the key news stories impacting Avalo Therapeutics this week:

  • Positive Sentiment: BTIG Research maintained a Buy rating while reducing its price target to $10 from $58. The revised target still implies meaningful upside from the referenced $7.45 share price. BTIG Research rating information
  • Positive Sentiment: Wedbush cut its price target to $22 from $34 but retained an Outperform rating, indicating continued confidence in Avalo’s longer-term opportunity despite near-term competitive concerns. Wedbush adjusts Avalo price target
  • Neutral Sentiment: Guggenheim reaffirmed its Neutral rating, while HC Wainwright separately reaffirmed Neutral in another research update. These actions suggest limited conviction following the recent decline. Guggenheim rating information HC Wainwright rating information
  • Neutral Sentiment: Trading in AVTX was temporarily halted under a volatility-related LULD pause, highlighting elevated short-term trading risk but providing no fundamental update.
  • Negative Sentiment: HC Wainwright downgraded Avalo from Buy to Neutral, removing a bullish analyst stance. HC Wainwright downgrades Avalo
  • Negative Sentiment: Phase III results from AbbVie in hidradenitis suppurativa appear to have raised the competitive bar for Avalo’s AVTX-009 program, weighing on the stock and contributing to broader analyst price-target reductions. AbbVie phase III data subdue Avalo shares

About Avalo Therapeutics

(Get Free Report)

Avalo Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for immune-mediated and inflammatory diseases. The company’s research and development programs are intended to address conditions with significant unmet medical needs.

Avalo’s lead product candidate is AVTX-009, a fully human monoclonal antibody designed to inhibit interleukin-1 beta, an inflammatory cytokine involved in several immune-related disorders. The candidate is being evaluated for potential treatment of hidradenitis suppurativa, a chronic inflammatory skin disease, and other inflammatory conditions.

The company was formerly known as Cerecor Inc and adopted the Avalo Therapeutics name in 2021.

Featured Articles